Non-alcoholic fatty liver disease
The DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) refers to the accumulation of hepatic steatosis not due to excess alcohol consumption. The prevalence of NAFLD is up to 30% in developed countries and nearly 10% in developing nations, making NAFLD the most common liver condition in the world. The pathogenesis of NAFLD is related to insulin resistance and, thus, it is frequently found in individuals who have central obesity or diabetes. Insulin resistance and excess adiposity are associated with increased lipid influx into the liver and increased de novo hepatic lipogenesis, promoting hepatic triglyceride accumulation. Defects in lipid utilization via mitochondrial oxidation and lipid export may also contribute to hepatic lipid build-up. Adipocytokine alterations, lipotoxicity from saturated fatty acids and fructose have been all been implicated in causing hepatocyte injury in NAFLD through pathways involving oxidative and endoplasmic reticulum stress. Clinically, NAFLD is commonly asymptomatic and frequently detected incidentally by blood liver function tests or imaging performed for other reasons. Subjects with NAFLD have a higher mortality rate than the general population and are at increased risk of developing cardiovascular disease and diabetes in the future. Histologically, NAFLD occurs as a spectrum from mild hepatic steatosis only, to non-alcoholic steatohepatitis (NASH) characterized by hepatocellular injury and inflammation, to cirrhosis. A diagnosis of NASH with associated fibrosis heralds a more significant prognosis as it is more likely to progressive to cirrhosis with complications of hepatic failure and hepatocellular carcinoma. Currently, the diagnosis of NASH requires a liver biopsy, however, serum based markers of hepatocyte apoptosis such as cytokeratin-18 fragments offer promise as accurate non-invasive diagnostic tests. Treatment of NAFLD revolves around addressing concomitant metabolic risk factors and improving insulin resistance through weight loss measures and exercise. Insulin sensitizing agents such as pioglitazone and anti-oxidant agents such as vitamin E show some promise in improving liver histology in patients with NASH, however, the long-term benefit of these medications has not been demonstrated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–215 of 215
Minervini, M. I., Ruppert, K. M., Fontes, P., Volpes, R., Vizzini, G. B., de Vera, M. E., Gruttadauria, S., Miraglia, R., Pipitone, L., Marsh, J. W., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.030 · Cited by 106
Kantartzis, K., Rittig, K., Balletshofer, B. M., Machann, J., Schick, F., Porubská, K., Fritsche, A., Häring, H., & Stefan, N. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.067397 · Cited by 105
Preoperative donor liver biopsy for adult living donor liver transplantation: Risks and benefits
Nadalin, S., Malagó, M., Valentín-Gamazo, C., et al. (2005) · Liver Transplantation · doi:10.1002/lt.20462 · Cited by 99
Subacute liver failure in obese women
Caldwell, S. H., & Hespenheide, E. E. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04279-x · Cited by 98
Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury?
Evans, C. D. J., Oien, K. A., MacSween, R. N. M., & Mills, P. R. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.9.689 · Cited by 95
Roldán-Valadéz, E., Favila, R., Martínez-López, M., Uribe, M., Ríos, C., & Méndez‐Sánchez, N. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.018 · Cited by 94
Romeo, S., Huang-Doran, I., Baroni, M. G., & Kotronen, A. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328338ca61 · Cited by 90
Malik, R., Chang, M., Bhaskar, K. R., Nasser, I. A., Curry, M. P., Schuppan, D., Byrnes, V., & Afdhal, N. H. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05731.x · Cited by 87
Non‐alcoholic fatty liver disease – a common and benign finding in octogenarian patients
Kagansky, N., Levy, S., Keter, D., Rimon, E., Taiba, Z., Fridman, Z., Berger, D., Knobler, H., & Malnick, S. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.0969.x · Cited by 86
Kallwitz, E. R., Guzman, G., TenCate, V., Vitello, J., Layden-Almer, J., Berkes, J., Patel, R., Layden, T. J., & Cotler, S. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.12 · Cited by 70
Leptin: The Prototypic Adipocytokine and its Role in NAFLD
Procaccini, C., Galgani, M., Rosa, V. D., Carbone, F., Rocca, C. L., Ranucci, G., Iorio, R. F., & Matarese, G. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791208884 · Cited by 67
Liver Transplantation After Jejunoileal Bypass for Morbid Obesity
Lowell, J. A., Surendra, S., Ghalib, R., Caldwell, C., White, F. V., Peters, M., & Howard, T. K. (1997) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(01)00894-8 · Cited by 56
Kayadibi, H., Gültepe, M., Yaşar, B., İnce, A. T., Özcan, Ö., İpçioğlu, O. M., Kurdaş, O. Ö., Bolat, B., Benek, Y. Z., Güveli, H., et al. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0535-0 · Cited by 52
An Editorial Update: Annus horribilis for Vitamin E
Guallar, E., Hanley, D. F., & Miller, E. R. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-2-200507190-00014 · Cited by 34
Leptin, liver, and obese mice—Fibrosis in the fat lane
Anania, F. A. (2002) · Hepatology · doi:10.1053/jhep.2002.34359 · Cited by 33
Cited by
Wang, Q., Ou, Y., Hu, G., Wen, C., Yue, S., Chen, C., Xu, L., Xie, J., Dai, H., Xiao, H., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14938 · Cited by 309
The role of growth hormone and insulin-like growth factor-I in the liver
Takahashi, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071447 · Cited by 193
IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner
Nishizawa, H., Iguchi, G., Fukuoka, H., Takahashi, M., Suda, K., Bando, H., Matsumoto, R., Yoshida, K., Odake, Y., Ogawa, W., et al. (2016) · Scientific Reports · doi:10.1038/srep34605 · Cited by 164
Chen, H., Wang, J., Li, Z., Lam, C. W. K., Xiao, Y., Wu, Q., & Zhang, W. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16122192 · Cited by 112
Postprandial lipemia as a cardiometabolic risk factor
Pirillo, A., Norata, G. D., & Catapano, A. L. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.909394 · Cited by 108
Metadata
- Authors
- Smith, B. W., & Adams, L. A.
- Venue
- Critical Reviews in Clinical Laboratory Sciences
- Publisher
- Informa UK Limited
- Published
- 2011-06
- Volume
- 48
- Issue
- 3
- Pages
- 97-113
- ISSN
- 1040-8363 (ISSN-L)
- 1549-781X
- OpenAlex
- W1986800512
- Cited by
- 285
- References
- 215
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.